Matrixx settles Zicam suits
This article was originally published in The Tan Sheet
Executive Summary
Matrixx has reached a settlement agreement intended to end 90% of the product liability litigation related to the firm's ZicamCold Remedy Nasal Gel, the company announces Jan. 19. The suits, filed in April 2004 in Arizona state court, involve approximately 340 plaintiffs who allege that use of the cold product caused them to lose their sense of smell. As a result of the settlement, the plaintiffs will dismiss their case with prejudice in return for an undisclosed sum of money. The individual amounts will be determined by medical protocol, Matrixx adds. The firm expects to pay a total of $12 mil. to fund the program; in order to go ahead with the settlement, 95% of the plaintiffs must accept the terms within two months, according to the firm. The company will "continue to fight" related litigation in Alabama and Colorado, a company spokesperson said (1"The Tan Sheet" Nov. 13, 2004, p. 13)...
You may also be interested in...
Zinc Gluconate Sprays Challenged In Lawsuits; Matrixx Defends Zicam Safety
The safety of zinc gluconate sprays has been called into question by a recent spate of lawsuits alleging that the products cause users to lose their sense of smell
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.